Table 3.
No. (%) of Patients With Guideline-Concordant Carea |
|||
---|---|---|---|
Risk Factor | Intervention | Control | OR (95% CI)b |
Overall (any risk factor) | 564 (25.4) | 675 (22.4) | 1.194 (1.005–1.419) |
Individual risk factors | |||
History of peptic ulcer disease | 118 (30.0) | 104 (25.9) | 1.314 (0.920–1.877) |
Any concomitant medicationc | 394 (26.8) | 477 (23.3) | 1.232 (0.998–1.521) |
Low-dose aspirin | 228 (25.0) | 254 (20.8) | 1.298 (1.041–1.618) |
Other concomitant medicationd | 166 (29.7) | 223 (27.1) | 1.160 (0.875–1.537) |
Age ≥75 y | 171 (20.9) | 253 (19.8) | 1.043 (0.826–1.316) |
CI=confidence interval; OR = odds ratio.
a Traditional nonsteroidal anti-inflammatory drug was discontinued and/or a new gastroprotective medication was coprescribed.
b For patients with risk factor vs patients without risk factor, controlling for age, sex, and number of office visits during study, and clustering by clinician and practice.
c Anticoagulant, antiplatelet medication (including aspirin), and/or systemic corticosteroid.
d Other than low-dose aspirin.